Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Notice of Interim Results

RNS Number : 1235E
Redx Pharma plc
04 May 2017
 

4 May 2017

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company")

 

Notice of Interim Results

 

Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that its interim results for the six months ended 31st March 2017 will be announced on Wednesday 17th May 2017.

 

Dr. Neil Murray, Chief Executive Officer, and Andrew Booth, Interim Finance Director, will host a presentation and conference call for analysts and investors at 12:30pm BST / 7:30am EDT on the day of results at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG. The presentation for the call will be made available on the Company website (www.redxpharma.com) in advance of the call.

 

For further information, please contact:

Redx Pharma Plc


Neil Murray, Chief Executive Officer

T: +44 1625 469 900 

Karl Hård, Head of Investor Relations &

Corporate Communications

T: +44 7491 651 406

 

Cantor Fitzgerald Europe (Nomad & Broker)

 

T: +44 20 7894 7000

Phil Davies/ Michael Reynolds

 



WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

Consilium Strategic Communications

 T: +44 20 3709 5700

Amber Fennell/ Matthew Neal/ Melissa Gardiner


 

 

About Redx Pharma Plc

Company website: www.redxpharma.com 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORAJMBTMBBMTIR



Redx Pharma Plc Timeline

CN Research
April 06 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use